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Abstract
The 18 kDa translocator protein (TSPO), previously known as the peripheral benzodiaz-
epine receptor, is expressed in the injured brain. It has become known as an imaging
marker of “neuroinflammation” indicating active disease, and is best interpreted as a
nondiagnostic biomarker and disease staging tool that refers to histopathology rather than
disease etiology. The therapeutic potential of TSPO as a drug target is mostly based on
the understanding that it is an outer mitochondrial membrane protein required for the
translocation of cholesterol, which thus regulates the rate of steroid synthesis. This
pivotal role together with the evolutionary conservation of TSPO has underpinned the
belief that any loss or mutation of TSPO should be associated with significant physi-
ological deficits or be outright incompatible with life. However, against prediction, full
Tspo knockout mice are viable and across their lifespan do not show the phenotype
expected if cholesterol transport and steroid synthesis were significantly impaired. Thus,
the “translocation” function of TSPO remains to be better substantiated. Here, we discuss
the literature before and after the introduction of the new nomenclature for TSPO and
review some of the newer findings. In light of the controversy surrounding the function
of TSPO, we emphasize the continued importance of identifying compounds with con-
firmed selectivity and suggest that TSPO expression is analyzed within specific disease
contexts rather than merely equated with the reified concept of “neuroinflammation.”
MICROGLIA AND BRAIN IMAGING
Active brain disease causes a change in the functional state of
microglia. This state change is associated with the de novo expres-
sion of the mitochondrial 18 kDa translocator protein (TSPO; or
peripheral benzodiazepine receptor; PBR), a binding site for which
selective high-affinity compounds were developed in the early
1980s (27, 99–101). This discovery was the starting point for
the systematic development of in vivo imaging of cellular
(nonneuronal) brain pathology (Figure 1). The principles underly-
ing brain imaging based on detecting binding sites, such as
TSPO, that are predominantly expressed by microglia focally and
along anatomical neural pathways have received much attention in
recent years [(15, 16, 20); Figures 2, 3 and 4].
The sustained interest in TSPO ligands for neuroimaging is due
to the fact that during active disease, the expression of this protein
is upregulated from a very low baseline. This is in direct contrast to
neuroreceptors which are usually downregulated, their loss often
correlating with neurological or cognitive deficits. However,
increased regional TSPO expression in the brain typically covaries
with disease state and activity rather than clinical deficit and,
therefore, does not map easily onto established disease classifica-
tions. In this sense, TSPO is a nondiagnostic biomarker that is
best interpreted in the context of histopathology and only secondary
to disease etiology. A substantial number of clinical trials are
now being conducted, the majority of which are using in vivo
measurements of TSPO expression as biomarkers of disease pro-
gression or therapeutic efficacy (Figure 5; Table S1 in Supporting
Information).
The lexical change (Table 1) from the operational definition of
“peripheral benzodiazepine receptor or binding site” to “18 kDa
translocator protein TSPO” emphasizes one physiological func-
tion, the “translocation” of cholesterol and essential rate determin-
ing step in the synthesis of steroids, over other proposed functions.
Research into the therapeutic potential of TSPO generally assumes
this to be the operant mechanism of drug action (23, 151–153).
This review, however, is written at a time when new data have
become available which show that knocking out the Tspo gene
does not result in the phenotype expected if steroid synthesis was
indeed altered (19, 123, 163, 170). While there are clear limita-
tions, even with regard to global Tspo knockouts, to how far it is
possible to extrapolate to the protein’s function in the context of a
normal organism, it suggests that the “translocation” concept
needs to be rethought. Like the “neuroinflammation” concept, the
concept of “translocation” is critically dependent on the context
within which it is applied.
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Here, we provide an overview of the publication trends before
and after the introduction of the new nomenclature for TSPO, the
efforts to develop new TSPO ligands as well as some of the newer
findings. This review emphasizes that the continued development
of new or the reassessment of existing molecules, with confirmed
selectivity for TSPO, will be crucial to the further development of
the field at large.
THE 18 kDa TSPO, FORMERLY KNOWN
AS PBR
The 18 kDa TSPO has been implicated in many important
physiological functions, including cholesterol transport and
steroidogenesis (94, 125, 134), cellular respiration (77) and
immunomodulation (102). Increased binding of ligands selective
for TSPO has been observed at sites of central nervous system
(CNS) pathology, such as glioma (162, 165, 166, 179), multiple
sclerosis (21) as well as Alzheimer’s disease (AD) (38), and TSPO
ligand binding is now seen as a hallmark for microglial activation
in vivo. These observations have led to a surge in the development
of TSPO-specific ligands appropriate for imaging and with poten-
tial for clinical applications. So far, none of these are in routine use
in the clinic, but the number of clinical trials recently initiated
(Table S1 in Supporting Information) indicates this may change in
the years to come.
Although much has been learned about this protein’s molecular,
biochemical and pharmacological properties, its exact role under
physiological and pathological conditions rests on a number of
assumptions which have come to be doubted in the wake of the
recent discovery that mice with tissue-specific or global knockout
of Tspo are, counter to expectation and prior indication in the
literature, neither embryonic lethal nor obviously impaired in their
production of steroids (123, 159, 170). The phenotype of these
animals appears to contradict a significant proportion of the so far
accepted evidence. As a note of caution, however, it is, important
to realize that constitutive or conditional gene knockout allows for
compensatory mechanisms either during early development or
through the presence of alternative pathways, and thus do not
necessarily falsify all claims about the role of TSPO in the adult
organism. In any case, 2014 marks a potentially pivotal year in
TSPO research and exciting controversial debate is imminent.
Given these recent developments in the field and the abundance
of reviews on the protein, it is not our intention to discuss all of
these proposed functions in detail; the reader is directed to other
articles (59, 67, 164) for a comprehensive overview. In this review,
we present a selection of the relevant literature, some prior to the
name change in 2006 (136) and some prior to the general accept-
ance of cholesterol translocation as TSPO’s defining function, and
summarize the efforts in developing selective TSPO-binding com-
pounds for use in neuroimaging.
HISTORICAL ASPECTS
Literature relating to TSPO encompasses many research fields,
highlighting a diverse range of reported functions and pathological
involvement, and the inherent complexity this entails. A timeline
of the early observations about TSPO prior to 2006 [before the
name change; (136)] can be seen in Table 2.
TSPO was discovered in 1977 by virtue of its ability to
bind the benzodiazepine diazepam in peripheral tissues (34). At
this time, the benzodiazepine Ro5-4864 was also identified as a
ligand for peripheral sites based on its inability to block binding
of diazepam at the central benzodiazepine receptor (CBR), while
blocking binding to an additional site in mitochondria of
peripheral tissues (34). Schoemaker et al (154) were among the
first to use this ligand for the characterization of the protein.
Figure 2. Adapted from (16). The transition of
parenchymal microglia from their normal state to
an activated state is accompanied by the de novo
expression of binding sites for (R)-PK11195, the
prototypical ligand originally used to describe the
presence and function of TSPO (100).
Transformation of microglia into ameboid cells,
such as seen after injuries involving neuronal cell
death (20), does not appear to lead to any further
increase in TSPO expression as measured by
binding of (R)-PK11195. This implies that the
dynamic range of signals based on the
expression of TSPO is best exploited at the point
of transition from resting to activated, but not
ameboid, microglia.
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The subsequent discovery of 1-(2-chlorophenyl)-N-methyl-
(1-methylpropyl)-3 isoquinoline carboxamide (PK11195), a
nonbenzodiazepine, TSPO-selective ligand, by PHARMUKA
Laboratories (Gennevilliers, France) (100) enabled a significant
increase in research productivity in characterizing the protein. In
the early 1990s, TSPO research began to increase in popularity,
coinciding with the publication of the first data implicating TSPO
in cholesterol transport and steroid synthesis (29, 94, 125, 138).
The protein was also cloned around this time (140, 161). Another
notable rise in the rate of publications can be observed around the
year 2000 when [3H]PK11195 binding was definitively localized
to activated microglia in the CNS (21), leading to the recognition
of PK11195 binding as a hallmark of microglial activation in vivo
and a subsequent increase in its use as an imaging tool in the
clinical neurosciences (“in vivo neuropathology”). Peaks in publi-
cation in subsequent years also reflect an increased interest in
TSPO ligands as therapeutic tools in various pathological condi-
tions, including anxiety (153) and cancer (110).
Initially named the “peripheral” or “peripheral-type benzodiaz-
epine receptor” as well as the number of other terms (Table 1), the
protein was renamed in 2006 by the “working group for renaming
the PBR” supported by Novartis (Basel, Switzerland). It proposed
“translocator protein (18 kDa)” or TSPO, together with prefixes,
mitoTSPO or nucTSPO, to denote either mitochondrial or nuclear
location, as the new nomenclature (136). The new nomenclature
was argued for on several grounds: (i) the transport, or
“translocation” of cholesterol as the preeminent role of the protein
over alternative functions, notably in energy metabolism (77, 133,
182); (ii) the sequence homology with the tryptophan-rich sensory
protein family (TspO) that function as light, oxygen and stress-
sensitive regulators of photosynthesis genes; and (iii) the applica-
bility of the name “TSPO” across species, noting that the rat gene
had been shown to substitute for its Rhodobacter sphaeroides
homolog TspO (182).
While this name change created clarity by restricting to a single
identifier, it marked a significant shift away from operational
Figure 3. Adapted from (17). (A) The blood–brain barrier (BBB) sepa-
rates the brain from the peripheral immune system. TSPO expression in
the brain is low to absent. (B) Pathologies causing disruption of the BBB
allow the influx of cells of the peripheral immune system. TSPO expres-
sion may be due to activated microglia or invading blood-borne
macrophages. (C) Noninflammatory neuronal injuries without obvious
BBB damage, such as after peripheral nerve lesion, evoke microglial
responses locally and in projection areas. TSPO expression occurs
throughout a network of neural tracts. (D) The presence of activated
microglia can confer regional “immune alertness” with the secondary
site-directed recruitment of, for example, circulating T-lymphocytes.
The neuronally triggered glial response may evolve toward a delayed
inflammatory response.
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definitions, such as PK11195 binding site or peripheral-type ben-
zodiazepine binding site, that were more cautious (66) in assigning
a “functional” definition to the protein. This new name signalled
the rationale for the first clinical phase II trials into the efficacy,
safety and tolerability of Emanupil (XBD173 Novartis; AC-5216
Dainippon Pharmaceutical), a new compound believed to modu-
late the “translocation”, and thus steroid regulating function of
TSPO. A trial in patients with generalized anxiety disorder was
registered in 2005 (http://clinicaltrials.gov/show/NCT00108836)
(91, 152).
KEY TRENDS IN THE TSPO LITERATURE
The precise examination of the relevant literature is challenging
because of the sheer number of publications as well as the ambi-
guity and diversity in names for the protein. Here, we have used
SCOPUS, one of the largest available online databases of peer-
reviewed scientific literature, to reveal trends in publishing and
Figure 4. From (37). The 3D [11C](R)-PK11195 binding potential map
projected onto the magnetic resonance image (MRI) of a patient with
herpes encephalitis indicates how the inflammation in the temporal lobe
and hippocampus (red) is associated with TSPO expression that tracks
throughout the limbic system beyond the focal injury. This is likely
to be due to Wallerian degeneration along the affected neural tract
system (blue = anterior cingulate; green = thalamus and brainstem;
purple = insular cortex; yellow = orbitofrontal gyri; the MRI subtraction
image in the right panel shows the volume losses, including the enlarge-
ment of the ventricles (v) of the destructive tissue pathology).
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Figure 5. Clinical trials listed under
“neuroinflammation” on clinicaltrials.gov as
of August 1, 2014.
Table 1. Aliases for translocator protein (18 kDa).
Abbreviation Name
PBR Peripheral benzodiazepine receptor
PTBR Peripheral-type benzodiazepine receptor
MBR Mitochondrial benzodiazepine receptor
IBP Isoquinoline binding protein
PBBS Peripheral benzodiazepine binding site
BPBS Benzodiazepine peripheral binding site
Bzrp Benzodiazepine receptor (peripheral)
Mdrc Mitochondrial DBI receptor complex
DBI Diazepam binding inhibitor
pk18 18 kDa PK (isoquinoline) binding subunit
Pkbs PK (or isoquinoline) binding site
ω 3 Omega 3 site
TSPO Translocator protein (18 kDa)
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citation rates of articles and the most prominent subject areas in
which TSPO-related research occurs. These bibliometric data are
indicative only as there are inherent limitations of automated data-
bases, including inconsistencies between the available services (1,
13, 57, 105). A search of the SCOPUS database returned a total of
2763 journal articles relating to TSPO (the individual search terms
and corresponding publication and citation rates are listed in
Table S2 and Figure S1 in Supporting Information). Of these,
approximately 89% were original articles and 11% were reviews.
The vast majority of research relating to TSPO falls into one or
more of four categories: biochemistry, genetics and molecular
biology; pharmacology, toxicology and pharmaceutics; medicine;
and neuroscience (Figure 6). These broad categories may be
roughly translated to research into the cellular functions of the
protein, applications of targeted drugs, research into the role of the
protein in disease, and more specifically, the role of the protein in
diseases of the nervous system. This demonstrates that much of the
interest in TSPO comes from researchers in the field of neurosci-
ence and mental health. However, it should be noted that despite
the change in nomenclature, a number of groups still use other
names either in addition to or instead of the term “TSPO”. There-
fore, literature searches intended to capture the entire field, includ-
ing foundational literature before the introduction of the new
nomenclature, require the use of several search terms. The overall
publications trends are shown in Figure 7 and the most cited pub-
lications are listed in Table 3.
THE Tspo GENE
The human Tspo gene is located on chromosome 22q13.3. It
consists of four exons and encodes 169 amino acids (106, 150). An
alternatively spliced variant named PBR-S lacks exon 2 and con-
tains an open reading frame that differs to TSPO (106). Despite the
observation that PBR-S mRNA is about 10 times more abundant
than Tspo, there is currently no experimental evidence for the
existence of a PBR-S protein. Recent studies have found that a
single-nucleotide polymorphism in exon 4, which causes a
nonconservative alanine to threonine substitution in the TSPO
protein, has an effect on ligand-binding affinity (93, 122, 132).
Thus, this genetic polymorphism must be considered when per-
forming quantitative imaging of TSPO using positron emission
tomography (PET).
Characterization of the Tspo promoter has revealed that it
resides within a CpG island and contains GC boxes but lacks
TATA or CCAAT elements (24, 106). A detailed description of
Tspo transcriptional regulation can be found in a recent review
Table 2. A selection of early discoveries in the TSPO field.
Abbreviations: ACTH = adrenocorticotropic hormone; AD = Alzheimer’s disease; ADC = adenine nucleotide carrier; ANT = adenine nucleotide
translocator; CSF = cerebrospinal fluid; DRG = dorsal root ganglion; MPTP = mitochondrial permeability transition pore; PBR = peripheral benzodiaz-
epine receptor; PET = positron emission tomography; TNF = tumor necrosis factor; TSPO = 18 kDa translocator protein; VDAC = voltage-dependent
anion channel.
Year Discovery Author/s
1977 Existence of peripheral benzodiazepine binding site Braestrup & Squires (34)
1981 Availability of radiolabeled Ro5-4864, binding in rat cerebral cortex Schoemaker et al (154)
1982 Demonstrates distinct population of Ro5-4864 binding in brain, predominantly on nuclear fraction Marangos et al (112)
1982 Localization of PBR to glia using Ro5-4864 Schoemaker et al (156)
1983 First use of PK11195 in vitro Le Fur et al (99)
1983 First use of PK11195 in vivo Le Fur et al (100)
1983 Shows Ro5-4864 is an agonist, PK11195 an antagonist Le Fur et al (101)
1983 Autoradiography demonstrates presence in olfactory bulb, median eminence, choroid plexus and
ependyma (CSF)
Benavides et al (27)
1983 Ro5-4864 binding in kidney and cerebral cortex (nuclear fraction) of rat Schoemaker et al (155)
1985 Hypophysectomy reduces Ro5-4864 binding in testis and adrenal gland, expression localised to cell type
reliant on pituitary input
Anholt et al (3)
1985 Distribution in neonate rats similar to adults, associated with mitochondria and oxidative phosphorylation Anholt et al (4)
1985 Differential and discrete localisation of PBR in endocrine organs De Souza et al (48)
1986 TSPO localizes to outer membrane of mitochondria Anholt et al (5)
1987 Porphyrins are endogenous ligands of TSPO Verma et al (174)
1989 PBR possibly involved in adrenal ACTH stimulated pregnenolone formation Besman et al (29)
1990 PBR functionally linked to Leydig cell steroidogenesis, possibly acting on cholesterol Papadopoulos et al (138)
1990 PBR linked to rate limiting step (cholesterol translocation) of steroidogenesis Krueger & Papadopoulos (94)
1992 18 kDa PBR protein associates with VDAC and ADC (ANT) McEnery (119)
1993 PBR may modulate inflammatory response in brain through effects on cytokine release Taupin et al (167)
1996 PBR ligands induce cell death via MPTP in presence of TNF Pastorino et al (141)
1998 Cholesterol recognition amino acid consensus sequence of PBR identified Li & Papadopoulos (103)
1999 Arsenite induces apoptosis via MPTP, an effect potentiated by PK11195 Larochette et al (98)
2000 PK11195 used in PET imaging of brain pathology Banati et al (21)
2001 PK11195 as PET tool for imaging microglial activation in early stages of AD Cagnin et al (37)
2002 PBR gene expression increased in DRG in peripheral axotomy model of neuropathic pain Xiao et al (180)
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(25). In addition to promoter-based transcriptional control, a short
interspersed repetitive element of the B2 family has been found to
generate an antisense transcript that downregulates expression of
Tspo in mouse cells (59).
Despite being evolutionarily conserved from bacteria to
humans, there are organisms such as Escherichia coli and the yeast
Saccharomyces cerevisiae that do not contain Tspo in their
genomes (103, 149). Fan et al have recently provided a review of
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Figure 6. Top 10 SCOPUS research areas by
citation rates of TSPO-related articles.
Neuroscience is one of the leading areas for
TSPO research.
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Table 3. Top 20 original articles ranked in order of citation rates. Citation information accessed through SCOPUS database.
Author Year Title Journal Times
cited
Cagnin A., Brooks D.J., Kennedy A.M., Gunn
R.N., Myers R., Turkheimer F.E., Jones T.,
Banati R.B.
2001 In-vivo measurement of activated microglia in dementia Lancet 503
Mcenery M.W., Snowman A.M., Trifiletti R.R.,
Snyder S.H.
1992 Isolation of the mitochondrial benzodiazepine receptor:
Association with the voltage-dependent anion channel and the
adenine nucleotide carrier
Proceedings of the
National Academy
of Sciences of the
United States of
America
453
Taupin V., Toulmond S., Serrano A., Benavides
J., Zavala F.
1993 Increase in IL-6, IL-1 and TNF levels in rat brain following
traumatic lesion. Influence of pre- and post-traumatic
treatment with Ro5 4864, a peripheral-type (p site)
benzodiazepine ligand
Journal of
Neuroimmunology
340
Anholt R.R.H., Pedersen P.L., De Souza E.B.,
Snyder S.H.
1986 The peripheral-type benzodiazepine receptor. Localization to the
mitochondrial outer membrane
Journal of Biological
Chemistry
330
Banati R.B., Newcombe J., Gunn R.N., Cagnin
A., Turkheimer F., Heppner F., Price G.,
Wegner F., Giovannoni G., Miller D.H., Perkin
G.D., Smith T., Hewson A.K., Bydder G.,
Kreutzberg G.W., Jones T., Cuzner M.L.,
Myers R.
2000 The peripheral benzodiazepine binding site in the brain in
multiple sclerosis. Quantitative in vivo imaging of microglia as
a measure of disease activity
Brain 325
Gerhard A., Pavese N., Hotton G., Turkheimer
F., Es M., Hammers A., Eggert K., Oertel W.,
Banati R.B., Brooks D.J.
2006 In vivo imaging of microglial activation with [11C](R)-PK11195
PET in idiopathic Parkinson’s disease
Neurobiology of
Disease
270
Ouchi Y., Yoshikawa E., Sekine Y., Futatsubashi
M., Kanno T., Ogusu T., Torizuka T.
2005 Microglial activation and dopamine terminal loss in early
Parkinson’s disease
Annals of Neurology 243
Li H., Papadopoulos V. 1998 Peripheral-type benzodiazepine receptor function in cholesterol
transport. Identification of a putative cholesterol
recognition/interaction amino acid sequence and consensus
pattern
Endocrinology 224
Hirsch T., Decaudin D., Susin S.A., Marchetti
P., Larochette N., Resche-Rigon M., Kroemer
G.
1998 PK11195, a ligand of the mitochondrial benzodiazepine receptor,
facilitates the induction of apoptosis and reverses
Bcl-2-mediated cytoprotection
Experimental Cell
Research
220
Turner M.R., Cagnin A., Turkheimer F.E., Miller
C.C.J., Shaw C.E., Brooks D.J., Leigh P.N.,
Banati R.B.
2004 Evidence of widespread cerebral microglial activation in
amyotrophic lateral sclerosis: An [11C](R)-PK11195 positron
emission tomography study
Neurobiology of
Disease
209
Cicchetti F., Brownell A.L., Williams K., Chen
Y.I., Livni E., Isacson O.
2002 Neuroinflammation of the nigrostriatal pathway during
progressive 6-OHDA dopamine degeneration in rats monitored
by immunohistochemistry and PET imaging
European Journal of
Neuroscience
209
Hardwick M., Fertikh D., Culty M., Li H., Vidic
B., Papadopoulos V.
1999 Peripheral-type benzodiazepine receptor (PBR) in human breast
cancer: Correlation of breast cancer cell aggressive phenotype
with PBR expression, nuclear localization, and PBR-mediated
cell proliferation and nuclear transport of cholesterol
Cancer Research 205
Krueger K.E., Papadopoulos V. 1990 Peripheral-type benzodiazepine receptors mediate translocation
of cholesterol from outer to inner mitochondrial membranes in
adrenocortical cells
Journal of Biological
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the likely evolution of TSPO (58). Ginter et al (69) suggest, based
on the observations in bacterial TspO, that the original role
of the protein may relate to porphyrin catabolism and the con-
sumption of reactive oxygen species (ROS), while cholesterol
transport (translocation) is a “moonlight function” found in higher
organisms.
STRUCTURE OF THE TSPO PROTEIN
An understanding of the structure of the TSPO protein pro-
vides valuable insight into its function and interaction with
ligands, a knowledge that is essential in the development of
pharmacological interventions that target TSPO. The current
model of TSPO describes it as an integral membrane protein
consisting of five transmembrane alpha helices, an extra-
mitochondrial C-terminal, an intramitochondrial N-terminal, two
extramitochondrial loops and two intramitochondrial loops, for
which Jaremko et al have recently been able to provide con-
firmatory data (84).
Structure of the TSPO monomer
The five putative transmembrane domains of TSPO were initially
indicated by hydropathy analysis of the human TSPO amino acid
sequence, which indicated five hydrophobic stretches that were
each predicted to span one layer of the membrane bilayer (28). The
use of site-directed mutagenesis and labeling techniques provided
further evidence of five transmembrane domains; however, it was
predicted that these regions would span the entire membrane
bilayer (85). Early molecular dynamics simulations predicted that
the five transmembrane regions had an alpha helix structure (28).
This has been supported by a nuclear magnetic resonance (NMR)
study of peptide fragments representing the five putative
transmembrane regions of the mouse TSPO (126). Furthermore,
circular dichroism spectroscopy analysis of the whole mouse
TSPO protein revealed an alpha helical content of 45%, which is
close to the value of 53% predicted if transmembrane domains
make up 100 of 169 amino acids in the TSPO sequence (126). It is
also interesting to note that the binding of the TSPO ligand
PK11195 increases the helical content from 45% to 52% (126).
While the tertiary fold of the whole TSPO in detergent micelles
was too unstable for further NMR study of tertiary structure, the
addition of a high concentration of PK11195 did have a stabilizing
effect (126).
TSPO has a short intramitochondrial N-terminal and a longer
extramitochondrial C-terminal (28, 85). Currently, there is a lack
of information on the structure of the N-terminal. However, con-
siderable effort has gone into modeling the C-terminal because of
its potential role as a TSPO-binding site for cholesterol (82, 103,
104). A cholesterol recognition/interaction amino acid consensus
sequence (CRAC) has been identified on the C-terminal of TSPO,
supporting its involvement in cholesterol transport (103). NMR
analysis of a TSPO C-terminal peptide (amino acids 144–169)
indicated a helical conformation for the L144 to S159 fragment of
the peptide and a groove that could accommodate a cholesterol
molecule (82). Analysis of the amino acid sequence also indicates
that the C-terminal is highly charged (28, 85).
The five transmembrane domains of TSPO are joined by two
extramitochondrial and two intramitochondrial loops. Differential
labeling of amino acids indicated that loops one and three were
located on the cytoplasmic side of the membrane, while loops two
and four were facing the inside of the mitochondria (85), in agree-
ment with earlier predictions (28). However, structural information
about these loops is currently less detailed than for the trans-
membrane domains and experimental studies of the structure of
the loop regions are still lacking. Investigations into the binding
sites of TSPO ligands have provided some additional information
about the interhelix loops and are described in more detail in the
succeeding text.
The functional model first proposed by Bernassau et al (28)
supports the hypothesis that TSPO can act as a cholesterol trans-
porter. It also indicates that TSPO has a channel structure to
facilitate this transport. Molecular dynamics simulations indicated
that the five transmembrane alpha helices may form a channel
approximately 3–4 Å wide, which could accommodate a choles-
terol molecule (28). Homology modeling using the crystal struc-
ture of apolipophorin III, and docking with cholesterol using shape
fitting, further indicates that TSPO monomer forms a molecular
channel that can transport a single cholesterol molecule (152).
Furthermore, the 10-Å resolution structure of bacterial homologue
TspO provides evidence that the transmembrane alpha helices are
arranged to form a channel structure for the translocation of mol-
ecules across the membrane (92). Recent successful structure
determination using the prototypical TSPO ligand PK11195 to
stabilize the protein (84) substantially validates earlier predictions
of the structure of TSPO.
Monomeric and oligomeric arrangement
of TSPO
TSPO is functional as a monomer (95); however, there is also
evidence that it forms oligomeric complexes with itself and other
proteins (49, 168). TSPO monomers are able to bind PK11195 and
cholesterol (95) and it has also been suggested that TSPO forms
homo-oligomers which may be important in cholesterol binding
and transport (49, 168). The formation of oligomers has been
correlated with an increased presence of ROS, which are thought
to induce covalent bonding of TSPO monomers (49). In addition,
recent transmission electron microscope images of negatively
stained mouse TSPO reconstituted into lipid have revealed the
presence of circular objects that are likely to be the association of
at least four TSPO monomers (168).
There is evidence that the bacterial homologue TspO
from R. sphaeroides forms homodimers in the presence of
protoporphyrinogen (181), which is further supported by structural
evidence that TspO forms dimers when reconstituted into helical
crystals (92). In both mammals and bacteria, it has been proposed
that the formation of TSPO oligomers is a dynamic process that
may be associated with ligand binding and transport function (49,
181); however, some function can still be retained in its mono-
meric form (49, 95).
The stabilizing effect of PK11195 on the protein reported by
Jaremko et al (84) was not seen with bacterial TspO, suggesting
that the PK11195 interaction relates to the cholesterol-associated
functions of the protein expressed in mammals, and is due to
differences in the tertiary and quaternary structure of TSPO not
seen in bacteria (83).
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TSPO association with other proteins
While TSPO can function as an isolated monomer or in homo-
oligomers, in mitochondria it is also believed to form a trimeric
complex with the 32 kDa voltage-dependent anion channel
(VDAC) and the 30 kDa adenine nucleotide carrier (119).TSPO has
also been implicated as part of the mitochondrial permeability
transition pore (MPTP), reflecting its putative role in apoptosis
(172). Early studies also revealed a possible complex with a 10 kDa
(30) and 43 kDa (47) protein that was labeled by high-affinity
ligands for the 18 kDaTSPO; however, the identity of these proteins
has not been elucidated. Additionally, there is evidence that TSPO
interacts with other proteins and peptides including peripheral
benzodiazepine receptor-associated protein 1 (PRAX-1) (65), ste-
roidogenic acute regulatory protein (StAR) (76), peripheral beno-
diazepine receptor-associated protein (PAP7) (108) and diazepam
binding inhibitor (DBI) (71) (Table S3 in Supporting Information).
Ligand binding sites
In addition to binding putative endogenous ligands such as cho-
lesterol and protoporphyrin IX, TSPO binds a range of synthetic
ligands. These compounds encompass a range of structural
classes including benzodiazepines, isoquinoline carboxamide
derivatives, imidazopyridines, benzothiazepines, benzoxazepines,
indole acetamide derivatives, phenoxyphenylacetamide deriva-
tives, pyrazolopyrimidines and vinca alkaloids (81).
The binding sites of the benzodiazepine Ro5-4864 and the
isoquinoline carboxamide derivative PK11195 on TSPO have been
investigated using site-directed mutagenesis, which revealed that
the two ligands have distinct but overlapping binding sites that
involve amino acid residues on the first cytoplasmic loop and the
C-terminal (60) (Figure 8). Further predictions of ligand binding
sites on TSPO were made using molecular modeling and analysis
of structure–activity relationships (9). The binding site for Ro5-
4864 likely includes the residues R24, G29, L37, K39, P40, S41,
W42, W107 and W161, while the PK11195 binding site includes
the residues R24, G29, L31, L37, P40, S41, W42, W107 and W161
(9). Furthermore, the binding site of the imidazopyridine alpidem
is predicted to include the residues G29, L31, L37, S41, W42,
W107 and W161 (9). While molecular modeling has provided a
useful prediction of the structure of the ligand binding sites,
experimental studies of the structure of the loop regions are still
lacking.
Figure 8. The topology of TSPO in the membrane, with amino acids involved in the binding of Ro5-4863, PK11195, Alpidem and the CRAC domain
highlighted.
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FUNCTIONAL ROLES OF TSPO
Cholesterol transport and steroid biosynthesis
Although TSPO has been linked to many physiological processes,
including immunomodulation (102), metabolism and cellular res-
piration (5, 77), by far the most widely accepted role of this protein
is the one in cholesterol transport and steroid synthesis. Since the
first observations were made (29, 94, 125, 138), this idea has been
extensively explored.
The fact that TSPO is located in steroid-synthesizing cell types
in endocrine organs itself suggested a role in endocrine function.
Although the steroidogenic process had been well characterized
previously, there were still lingering questions. While at the time it
was known that steroid synthesis takes place in mitochondria
and requires cleavage of cholesterol into pregnenolone by the
cytochrome P-450 side-chain cleavage enzyme on the inner
mitochondrial membrane, it was still unclear how cholesterol is
transported from the outer to inner mitochondrial membranes, a
process found to be the rate-limiting step for this reaction (147).
Being located on the outer mitochondrial membrane (OMM) of
steroid-synthesizing cells, TSPO became a potential candidate for
fulfilling this role.
An important first study that explored this was that by
Papadopoulos et al (138), which measured the production of pro-
gesterone in MA-10 Leydig cells in the presence of known TSPO
ligands including the isoquinoline carboxamides PK11195,
PK14067, PK14068, as well as the benzodiazepines Ro5-4864,
diazepam, flunitrazepam, clonazepam, zolpidem and flumazenil at
a range of concentrations. These ligands not only increased secre-
tion of progesterone, but also did so to a degree that correlates with
TSPOs pharmacological profile (i.e., PK11195 increased proges-
terone production the most, with flumazenil having no effect). A
subsequent study using isolated mitochondria found that PK11195
stimulated hormone synthesis at the mitochondrial level by acting
on cholesterol already available in the OMM, as addition of excess
cholesterol to media did not enhance steroid synthesis (94). The
same study employed digitonin titration of mitochondrial mem-
branes to demonstrate that PK11195 exerted its effects by enhanc-
ing translocation of cholesterol from outer to inner mitochondrial
membranes, the rate-limiting step in steroid synthesis. Antisense
knockout studies have also linked TSPO to steroid production (90).
A cholesterol recognition site, identified by deletion of the
cytosolic carboxyl terminal of TSPO, has been identified, and
termed the CRAC domain (103). These studies brought about a
surge in publication activity based on this new theory.
However, it is still unclear whether TSPO is necessary or suffi-
cient for steroid synthesis. Multiple pathways for cholesterol trans-
port have been suggested (120), with the protein StAR now being
shown to play a crucial role (121). An essential steroidogenic role
for StAR is clear, as mice with the gene knocked out die soon after
birth of adrenocortical insufficiency (40), and many humans with
congenital lipoid adrenal hyperplasia possess a nonfunctional
StAR gene (107).
Although mutations in the Tspo gene have not been linked
directly to disease states involving impaired steroid production, the
Tspo gene is evolutionarily highly conserved (45, 181) which has
been interpreted as indicating a nonredundant, integral function for
the organism. While earlier reports of embryonic lethal outcomes
from Tspo knockout studies indeed appeared to confirm this
assumption (135), more recent work shows that Tspo is an ancient
but nonessential gene (18, 19, 123, 159, 163, 170). In light of the
evolutionary pressure to conserve the gene, its documented influ-
ence on steroidogenesis and the previously observed embryonic
lethality caused by the knockout of either Tspo (135) or the endog-
enous PBR/TSPO ligand, Acyl-CoA binding protein (97), the sur-
vival and overtly normal phenotype of a global Tspo knockout
animal might seem unexpected. However, the evolutionary preser-
vation of an ancient gene does not necessarily imply that it is
essential, nor that an ancient and nonessential gene is less likely
to be relevant for the emergence of disease. On the contrary,
phylostratigraphic analysis of the human genome suggests that
nonessential ancient genes predominate among the disease-
associated genes (53). PBR/Tspo may therefore be considered a
nonessential disease gene that lies at the functional periphery of the
interactome, with more limited direct interactions than an in utero
essential hub gene (22). Consequently, the functional impact on a
Tspo knockout would be predicted to be discreet.
It has been hypothesized that TSPO is involved in the produc-
tion of steroids in the brain (137). Neurosteroids have been found
to exert anxiolytic effects by allosterically modulating γ-amino
butyric acid (GABA) neurotransmission (151). Altered PK11195
binding has previously been found on platelets (176) and lympho-
cytes (61, 62) of patients with anxiety disorders. Together, these
data suggest that TSPO plays a role in neurosteroid production,
hence affecting anxiety states, making it a potential target for
anxiolytic drugs. New TSPO ligands have been shown to have
anxiolytic effects in animal models (46, 153) and human trials
(153). High doses of the ligand XBD173 were shown to exert
quick acting anxiolytic effects without sedation and withdrawal
effects in a male cohort subjected to cholecystokinin tetrapeptide-
induced anxiety (153), while the ligand N,N-di-n-propyl-2-(4-
methylphenyl)indol-3-ylglyoxylamide was shown to stimulate
allopregnanolone production and exert anxiolytic effects in rats
subjected to the elevated plus maze (46). However, XBD173 has
been demonstrated by PET to bind with mixed affinity in the
human brain (131), raising the possibility that its anxiolytic effects
involve binding sites other than TSPO.
TSPO in cell cycle and cellular bioenergetics
Early studies found that the binding site for isoquinoline
carboxamides (such as PK11195 and irreversible photosensitive
ligand PK14105) was an 18 kDa protein that formed complexes
with a number of other proteins (51, 109, 118, 119). Two proteins
of 30 kDa and 32 kDa were subsequently confirmed to be the
VDAC and the adenine nucleotide carrier (also known as the
adenine nucleotide translocator), two candidate regulatory compo-
nents of the MPTP (119). The MPTP is a nonspecific pore that
opens in response to mitochondrial stress and allows the free
passage of molecules under 1.5 kDa, resulting in the uncoupling of
oxidative phosphorylation (74). Thus, the MPTP is a crucial regu-
lator of cell death, in particular by apoptosis (98, 141). A series of
studies has demonstrated a modulating effect of TSPO ligands on
apoptosis in cell culture [for reviews see (172, 173)], which indi-
cates that the protein may have a role in modulating the
mitochondrial permeability transition. This implication of a role in
apoptosis is significant, as increased TSPO expression has been
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demonstrated in neoplastic cell types and in tumors (162). The
potential for TSPO ligands to induce apoptosis in neoplastic cells
that have increased expression of the protein has made it a prom-
ising target for anti-tumorigenic therapies. PK11195 has already
been used experimentally as an anti-tumor agent (2, 96). However,
a recent study has called much of this evidence into doubt; the
group found that mitochondria isolated from mouse livers with a
conditional deletion of Tspo were just as capable of undergoing the
permeability transition as the controls, suggesting TSPO may not
have as integral a role as once thought (159).
It has recently been reported that TSPO also has a role in
modulating gluconeogenesis, and thus has relevance for the patho-
physiology of obesity and diabetes. While screening the effect of
2400 bioactive compounds on gluconeogenesis in zebrafish (73),
the TSPO ligands PK11195 and Ro5-4864 were identified as com-
pounds that decrease glucose and reduce energy consumption,
suggesting a role for TSPO in glucose metabolism. Gut et al (73)
further demonstrated that PK11195 and Ro5-4864 (in micromolar
concentrations) reduced blood glucose in 24-h fasted mice, and
reduced weight gain and improved glucose tolerance in a mouse
model of high-fat diet-induced obesity and diabetes (73). The
effect of PK11195 on glucose homeostasis suggests that TSPO
may have a role in cellular energy consumption, which may relate
to the function of mitochondria in energy production (e.g., adeno-
sine triphosphate (ATP) production). This could explain the seem-
ingly conflicting evidence derived from steroidogenic cell lines, as
changes in bioenergetics are likely to indirectly affect other cell
functions including steroid synthesis. However, at this stage, the
selectivity of the observed effects of the TSPO ligands PK11195
and Ro5-4864 remain to be tested at lower (nanomolar) concen-
trations. Likewise, the selectivity and specificity of the effects of
the ligands to TSPO require further investigation.
TSPO LIGAND DEVELOPMENT
Early characterization of selective ligands
TSPO was originally identified indirectly by the pharmacological
profile of its binding sites: (i) clonazepam acting as a weak inhibitor
(opposite to the central-type binding site); (ii) diazepam’s affinity
was significantly lower; and (iii) Ro5-4864 potently inhibited
binding (Figure 9). It was not until the availability of [3H]Ro5-4864
in 1981 that TSPO could be identified directly in experiments
utilizing radioligand binding and autoradiography. The subsequent
discovery of the nonbenzodiazepine ligand PK11195 and its ability
to potently displace Ro5-4864 from its binding sites (27, 99–101)
increased the scope of exploration.Although initial thermodynamic
studies indicated that Ro5-4864 was most likely to be an agonist or
partial agonist, and PK11195 an antagonist (101), subsequent
studies have shown PK11195 to have similar actions to Ro5-4864
(138). With these two tools, it became possible to begin to derive the
physiological and pharmacological significance of TSPO, espe-
cially because they were both found to bind in vivo (99).
TSPO has been found to have a ubiquitous organ distribution,
including adrenal gland, kidney, heart, platelets (154), lung, testis,
liver and muscle (112) and brown fat (4). In contrast to central ben-
zodiazepine binding sites, expression of TSPO is generally low in
the healthy brain, found mainly in the olfactory bulb, and nonparen-
chymal regions such as ependyma and choroid plexus (27, 68). A
significant increase in binding can be seen under pathological con-
ditions (156). Although the homogenization of tissue required for
radioligand binding prevented the easy identification of the specific
cell types responsible for binding in the organs mentioned earlier,
autoradiography has proven to be a more helpful tool, demonstrat-
ing increased binding in areas including the cortex of the adrenal
gland, ventricular tissue in the heart (4), interstitial tissue (including
Leydig cells) in the testis (48) and the distal tubules of the cortex and
ascending limb of the loop of Henle in the kidney (68). Hypophy-
sectomy in rats showed that TSPO is generally expressed on cells in
the adrenal gland and testis that rely on trophic influence from the
pituitary gland and produce steroid hormones (3).
Evidence for the subcellular localization of TSPO is conflicting.
An early study showed co-distribution of TSPO ligand binding
with cytochrome oxidase activity that alluded to mitochondrial
involvement (4), with subsequent studies using subcellular frac-
tionation techniques directly indicating the presence of TSPO
ligand binding on the mitochondrial fraction (5, 6). Although gen-
erally accepted as a mitochondrial membrane protein, evidence
suggests that there may be other subcellular locations for TSPO,
including nucleus (112, 155), plasma membrane (128) and an
undefined microsomal compartment (124, 127). Whether the dif-
ference in localization is due to technical differences or the tissue
tested remains unclear. It is interesting to note that PK11195 and
Ro5-4864 both bind to erythrocytes, even though these cells have
no mitochondria or nucleus (129). However, it is safe to say that
TSPO has a primarily mitochondrial location and this has been an
important factor in subsequent studies.
Ligands have again proven useful in determining the precise
mitochondrial location of TSPO. Digitonin titration with mito-
chondrial isolates, a previously well-documented technique, was
used by Anholt et al (5) to demonstrate the presence of PK11195
binding on the OMM by its co-release with the OMM marker
enzyme, monoamine oxidase. Other studies have confirmed this
using nondigitonin techniques (127). However, a study by
Mukherjee and Das (124) used both digitonin titration and osmotic
shock to isolate mitochondrial membrane compartments and found
that TSPO binding was present on the inner mitochondrial mem-
brane (IMM). High resolution electron microscopy images would
be helpful for clarifying the true location(s) of TSPO binding.
The above-mentioned ligands have been used to explore
many facets of TSPO. A photosensitive isoquinoline carboxamide
N
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Figure 9. Structures of diazepam and Ro5-4864.
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derivative, PK14105, was found to displace PK11195 and Ro5-
4864 and was used to isolate and visualize the 18 kDaTSPO protein
by gel electrophoresis (7, 51). The mechanism by which PK14105
irreversibly cross-links to the TSPO protein is unknown, but is
assumed to be a nucleophilic aromatic substitution by an amino acid
side chain functional group oriented in close proximity to the bound
ligand (51). This ligand was later used to isolate two important
proteins associated with TSPO (119). PK11195 and Ro5-4864 have
also been used to confirm cloning of rat (161) and bovine (140)
TSPO and as a tool for cloning human Tspo (150). They have also
been used to explore TSPO’s physiological significance, including
the protein’s most well-characterized role in steroid synthesis.
These two ligands have experienced varying use over time. While
PK11195 has been used extensively throughout the last 30 years,
publications using Ro5-4864 have been on the decline since the
early 1990s. This can be largely attributed to the high affinity of
PK11195 to TSPO across multiple species (12). Use of both ligands
has declined recently with the onset of a new league of ligands that
address drawbacks of the former ligands while maintaining high
affinity. Nonetheless, both are still considered the prototype ligands
to which all others are compared and much has been learned about
TSPO through their past and continued use.
Development of new synthetic ligands
With TSPO being implicated in so many physiological functions
and pathologies, extensive resources have been dedicated to the
discovery of new synthetic molecules with high affinity and selec-
tivity for the protein. Although the original intention was to
develop molecules as potential therapeutics by acting as modula-
tors of TSPO pharmacology, the emergence of radio- and
photoaffinity-labeled analogues as part of TSPO characterization
has resulted in exciting pharmacological, biochemical and in vivo
imaging applications. With respect to the latter, a significant
volume of literature relates to TSPO imaging applications in
inflammation, such as multiple sclerosis and infection, as well as
neurodegenerative disorders, cancer and heart disease.
The prototypical ligands for TSPO, Ro5-4864 and PK11195,
have been invaluable tools for the molecular and biochemical
characterization of the TSPO protein. In addition to potential
therapeutic applications, the carbon-11 analogues [11C]Ro5-4864
and [11C]PK11195 have been used to measure, quantify and
image increased TSPO receptor overexpression in neurode-
generative disorders (26) and in neoplastic tissue (162). TSPO
overexpression levels in platelets have also been examined as
potential indicators of anxiety and stress (54, 176) while [125/
131I]-PK11195 have been explored as potential imaging/
radiotherapeutic agents (2, 177).
However, initial PET imaging with [11C]Ro5-4864 in patients
with brain tumors did not show great promise because of large
amounts of nonspecific binding and low in vitro affinity in human
brain tissue (12). On the other hand, studies with [11C]PK11195 in
patients with brain tumors, AD, stroke and multiple sclerosis,
indicated improved in vivo pharmacokinetics as a PET radiotracer
compared with [11C]Ro5-4864, however, it too displayed poor
signal to noise ratio, low blood–brain barrier permeability and
high nonspecific binding (158). Attempts to enhance the
pharmacokinetic properties of PK11195 through derivatization as
well as labeling with the longer lived PET isotope fluorine-18 or
the single photon emission computer tomography (SPECT)
isotope iodine-123 were unsuccessful.
Radiolabeled TSPO ligands
A considerable number of diverse chemical entities with high
specificity and selectivity for TSPO have been developed in the last
30 years (152). All of these molecules were identified by their
ability to compete for binding sites against Ro5-4864 and
PK11195. As expected, the emergence of these diverse classes
of TSPO molecules has also prompted the development of
radiolabeled TSPO analogues using [11C]carbon, [123I]iodine
and [18F]fluorine. Consequently, more than 50 new TSPO
radioligands have been reported [for a review see (41, 42)] with
most being reported in the last decade and a trend toward
[18F]TSPO radioligands. A considerable number of these
radioligands have been developed to study the various conditions
associated with altered TSPO expression using PET and the related
imaging modality SPECT. Furthermore, the combination of TSPO
radiotracer formulations with high specific activity and low phar-
macological doses has had the added benefit of enabling truly
noninvasive PET or SPECT in vivo imaging, accelerating the pro-
gression to in vivo human studies.
The currently leading TSPO radiotracers include the N-benzyl-
N-(2-phenoxyaryl)-acetamide derivative [11C]-DAA1106 (79,
111, 184), the structural analogues [11C] pyridinylaceta-
mides, [18F]PBR06 (64), [18F]FEPPA (178), 2-phenylpyrazolo
[1,5-a]pyrimidineacetamide [11C]DPA-713 (80, 157) and the
2-phenylimadzo[1,2-a]pyridines [123I]-CLINDE (114) and [18F]
PBR111 (63). These have been developed with enhanced pharma-
cological and pharmacokinetic properties and reduced nonspecific
binding suitable for imaging TSPO receptors in vivo using PET or
SPECT. Furthermore, many of these radiotracers have demon-
strated superior imaging capability in imaging inflammatory pro-
cesses in both animal models of disease and in humans in
comparison with Ro5-4864 and PK11195. However, despite the
considerable improvements exhibited by these TSPO radiotracers,
most developed to date are less than ideal, primarily because of a
significant component of nonspecific binding stemming from an
unfavorable metabolism and nonspecific uptake of the radiolabeled
fragments in regions of interest.
Modeling studies have suggested three common hydrophobic
interactions with the tryptophan residues (W42, W107 and W161)
and a polar hydrogen bond interaction as a requirement for affinity
to TSPO (8, 43, 130). However, the same types of interactions are
also anticipated for the CBR with the main difference being the
spatial positioning of these interactions (8). Despite the limitation
of radionuclidic half-life (t = 20 minutes) and the complexity of
radiolabeling, nearly half of the pool of TSPO radiotracers reported
are [11C]carbon analogues. In general, convenience and the need
for preservation of the overall chemical structure have been argu-
ments in favor of [11C]carbon radiolabeling. The latter has mainly
been through the methylation on a hetero atom such as a nitrogen, as
in the first PET TSPO radiotracers [11C]Ro5-4864 and [11C]
PK11195 (39), or oxygen, as in [11C]DAA1106 (183), to provide
the structurally identical analogue. The introduction of other iso-
topes such as [18F]fluorine or [123I]iodine onto any of the large
variety of TSPO chemical structures available requires consi-
derable knowledge of the TSPO pharmacophore and extensive
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structure-activity studies of the chemical structure under considera-
tion. Even then, the introduction of [123I]iodine or [18F]fluorine
onto existing molecules for more convenient radiochemistry, wider
tracer distribution or extended SPECT or PET imaging, respec-
tively, may introduce pharmacological, biological and pharma-
cokinetic properties that are not always predictable.A clear example
of this is in the comparison between [11C]zolpidem and the analo-
gous [123I]iodozlopidem. [11C]zolpidem is a CBR selective ligand
that is labeled with [11C]carbon via methylation of the correspond-
ing dimethylacetamide (55). Substitution of the phenyl methyl
group of zoplidem with a phenyl iodo group gives iodozolpidem. In
vivo studies of radiolabeled [123I]iodozolpidem, in contrast to
[11C]zolpidem, showed that the modification resulted in a ligand
with characteristics of a TSPO ligand (89, 115). It was this impor-
tant discovery together with the limited pharmacological data
derived fromAlpidem that significantly influenced our research and
development on TSPO-specific molecules based on the
imidazopyridine type structure (a selection ofTSPO ligands is listed
in Table S4 of Supporting Information).
Radioligands of the imidazopyridine family
In the last two decades, our group has developed several TSPO-
selective radioligands that could be used for PET or SPECT
imaging; an extensive structure-activity study of molecular entities
spanning more than 10 different chemical families resulted in the
synthesis and evaluation of over 250 novel molecules (50, 86, 88),
of which over 50 displayed high nanomolar affinity for TSPO with
excellent selectivity over the CBR (Figure 10). From these, 22 novel
radiotracers bearing carbon-11 [11C], fluorine-18 [18F] and
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iodine-123 [123I] representing the imidazopyridines (87, 88),
[123I]CLINDE (87), [11C]CLINME (169) and [123I]CLINME
(116); the structurally related imidazopyridazines (88), 2-
phenylpyrazolo[1,5-a]pyrimidine acetamides (63) and [123I] N,N-
dialkyl-2-phenylindol-3-yl-glyoxylamides (78); as well as the
N-benzyl-N-(2-phenoxyaryl)-acetamide derivatives, were pre-
pared and extensively evaluated in rodents, with many of these
compounds displaying improved biological characteristics,
such as a higher target to background signal, faster clearance from
nonspecific tissue and improved metabolic stability relative to
[11C]PK11195 in in vivo animal studies (32, 52, 55, 63, 115). The
imidazopyridines were the most successful; five of these
radiotracers ([123I]-CLINDE, [123I]-CLINME, [11C]-CLINME,
[18F]-PBR111 and [18F]-PBR102) have further been evaluated in
several rodent animal models of disease (10, 11, 33, 113, 114, 160,
171) confirming that these radiotracers can image and measure
activated microglia/macrophage infiltration in the CNS. In addition,
we have combined and compared the results of in vitro ligand
binding, autoradiography, RT-qPCR (reverse transcription quanti-
tative real-time polymerase chain reaction) and immunohisto-
chemical staining with in vivo small animal SPECT and PET
imaging using our novel radiotracers [123I]CLINDE (113, 114) and
[18F]PBR111 in models of multiple sclerosis in rodents (experi-
mental autoimmune encephalomyelitis, EAE) (117). In this work,
we have demonstrated uptake of radioactivity in the spinal cord and
brain tissues from rodents with EAE, which directly correlated to
sites of inflammatory lesions and immunoreactivity for the acti-
vated microglia/macrophage and astroglia markers confirming the
use of in vitro and in vivo ligand binding to TSPO as a measure of
lesion activity in autoimmune CNS demyelinating diseases. Most
importantly, TSPO imaging using these radiotracers enabled us to
measure and quantify TSPO expression in activated microglia with
excellent correlation to in vitro immunohistological staining and
RT-qPCR results (117). Four tracers ([123I]-CLINDE, [18F]
PBR102, [18F]-PBR111 and [18F]PBR170) were progressed to
pharmacokinetic studies involving nonhuman primates while the
SPECT ligand [123I]CLINDE and the PET ligand [18F]PBR111
were found to display some of the most favorable in vivo properties
(175). These studies (unpublished data) indicate that unlike the
results obtained from rodents, both [18F]PBR102 and [18F]
PBR111 display similar pharmacokinetics in primates with some
defluorination observed for [18F]PBR111. The expected formation
of [18F]fluoroacetate following oxidative metabolism of the
O-ethyl group of PBR102, although present, was not as significant
in primates as that observed in rodents. The promising preclinical
data for [123I]CLINDE and [18F]PBR111 have allowed these
compounds to become candidates for further evaluation in humans
with neurodegenerative diseases such as Parkinson’s and multiple
sclerosis (44, 72, 185).
Radioligands are often metabolized by experimental subjects
during imaging. The metabolism of the ligands is thus a parameter
that must be considered for imaging quantification. Resulting
radiometabolites that also have affinity to the receptor being imaged
will distort the analysis, whereas high levels of radiometabolites
that enter the region of interest will decrease the potential sensitivity
of the radioligand. Strategic positioning of the radiolabel can mod-
erate these troublesome radiometabolites; however, knowing the
site of metabolic cleavage on the molecule is not always predictable
and is further complicated by species differences (145).
Metabolite studies
In vitro metabolic studies of the TSPO ligands CLINDE, PBR111,
PBR102 and the bioisosterically similar compound DPA-714,
using rat and human microsomes, have identified that the common
main metabolic pathway in this group is via N-dealkylation,
O-dealkylation and hydroxylation of aliphatics (142–144).
N-deethylation and hydroxylation derivatizes these ligands into
radiometabolites that resemble the parent (unmetabolized ligand)
and can compete with the receptor (Figure 11). Our work has
revealed that the N-deethylated [123I]CLINDE derivative has
affinity for TSPO (PBR IC50 = 10 nM, CBR IC50 = 104 nM)
(unpublished data). This may also have implications for other
dialkylated secondary amino TSPO radioligands, where the radi-
olabel is part of the N-dealkylated product.
As previously mentioned, many of the TSPO ligands were
derived from [11C]methylation of a nitrogen or an oxygen.
Dealkylation of these methyl groups results in the formation of
[11C]formaldehyde and [11C]carbon dioxide, which for brain
studies, does not interfere as these radiometabolites do not cross
the blood–brain barrier. In contrast, several of the [18F]
fluorinated TSPO radioligands are [18F]-O-fluoroalkylated deriv-
atives (PBR102, PBR111, DPA714, FEPPA and FEDAA1106).
O-dealkylation can result in an [18F]fluorinated aldehydes which
can subsequently be oxidized to their [18F]fluorinated acids.
Further metabolism of these acids can result in [18F]fluoride
which can accumulate in bone potentially complicating the
imaging analysis and decreasing the ability of the radioligand to
identify subtle changes to the receptor. However, the extent of
metabolism is dependent on species (142, 145); while it may
present a problem in one species, it may not be as significant in
another.
To further refine our established PET radioligands and con-
sidering the metabolic data, our group synthesized a new
[11C]imidazopyridine ligand, [11C]PBR170 (PBR IC50 4.5 nM,
CBR IC50 > 10 000 nM) (31, 56) (Figure 12). Similar to
[11C]CLINME, the [11C]carbon resides on the acetamide as a
[11C]methyl group. The other group on the acetamide is a fluoro
pyridine which serves to prevent the N-deethylation observed with
previous series of TSPO ligands. It also allows potential introduc-
tion of [18F]fluorine into the ligand via the fluoro pyridine as an
option for longer imaging times and also offers a comparison
between the different radiometabolites of the same tracer. In
general, an aromatic fluoride is less susceptible to defluorination.
Although O-deethylation may occur, the resulting phenolic
radiometabolite is expected to be more water soluble and unlikely
to enter the brain, while at the same time having a faster clearance
rate.
Preliminary results show that [11C]PBR170 shows saturable,
displaceable and specific binding in TSPO-rich tissues. The kinet-
ics and low nonspecific cerebral binding make this radiotracer
suitable for imaging TSPO-associated brain abnormalities (56).
Another complexity in assessing radioligand potential in
humans is due to a genetic polymorphism of TSPO (93, 132); there
are three types of binders within the population: high-, low- and
mixed-affinity binders (93, 131). The radioligands PBR28, PBR06
and DAA1106 differentiate between the high- and low-affinity
binders by approximately fifty-, seventeen- and four-fold, respec-
tively, despite all belonging to the same class of TSPO radioligands
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(131). In contrast, PK11195 binds at comparable levels across the
population. PBR111 and DPA713 were also evaluated and showed
an approximate fourfold difference. These findings have not
deterred further clinical evaluation of [18F]PBR111 in multiple
sclerosis patients (44, 146) as it still offers other advantages over
PK11195.
FUTURE DIRECTIONS FOR TSPO
IMAGING LIGANDS
Imaging the subtle changes in TSPO expression by PET or SPECT
requires the design of radioligands with exquisite sensitivity and
specificity, free of deleterious signal contributed by spurious
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metabolites. Accordingly, attempts to image diseases using
radiotracers that compromise this fine signal would be futile. With
so many applications and a plethora of novel TSPO radiotracers
available, it is an exciting time to extract the clinical value that
TSPO has to offer. Of the radiotracers that have already progressed
to human studies for neuroinflammation and neurodegenerative
diseases (42), there is still no single tracer that offers a clear
advantage over the rest for widespread use. This highlights the
need to further explore these TSPO radiotracers in the clinic while
attempting to further elucidate the nature of TSPO itself. With so
many questions to be answered, a better understanding of the
relationship between these molecules and the biological function
of TSPO is required. It also appears that we may have exhausted
the potential for ligand–receptor interactions to further character-
ize this enigmatic protein and focus now should be on its biologi-
cal characterization by other means.
CONCLUSION
A substantial part of the research relating to TSPO is focused on its
diagnostic utility in neuroimaging. It is, therefore, possible to
interpret the development of scientific knowledge around “TSPO
and neuroimaging” so far as the appropriation of concepts from
different fields. Starting with the rediscovery of microglia in the
1960s, the wider availability of immunohistochemical staining
techniques for microglia in the early 1990s led to the gradual
recognition that the brain was not an “immune-privileged” organ
and catalyzed the evolution of the “neuroinflammation” concept.
Since then, the “neuroinflammation” concept has found steadily
broadening applications, including to illnesses that traditionally
have been accompanied by disagreement in regard to construct
validity and nosology, such as schizophrenia (14, 36). Somewhat
similarly, the notion of “translocation” in the context of TSPO was
able to gather the many strands of evidence into a more unified
theory, where previously the role of TSPO could best be described
as “enigmatic” (67).
In the discussion around “neuroinflammation” and the
“translocator protein,” one witnesses the role and impact of lexical
changes in new scientific developments (148), which provides
“pragmatic ambiguity” (70) in the face of incomplete mechanistic
understanding. The problem of specific annotations of gene func-
tions is well recognized (66). More importantly, however, these
controversies point to a fundamental challenge in biology, namely
deciding the appropriate level at which a description allows con-
version of “data into knowledge and knowledge into understand-
ing” (35). Research into TSPO is arguably confronted with the
classical inverse problem; that is, how to arrive at a model of TSPO
function from observations at a higher level of complexity, for
example behavior. In this context, the theory that TSPO is a
“translocator” promised a welcome reduction in complexity. Yet,
the one important forward prediction based on this theory, namely
that a full Tspo knockout mouse should either be embryonic lethal,
as in fact had been reported (134), or substantially impaired
because of impaired steroid synthesis, has not held true. On the
other hand, from a “systems biological” perspective, the observa-
tion that Tspo is an ancient, nonessential gene could be interpreted
as support that its function is in fact an emergent property that
necessarily requires the context of other pathways and protein–
protein interactions.
Drug discovery marked the beginning of research into TSPO
and its role in physiology. With the availability of well-
characterized Tspo knockout animals with normal physiology
across their lifespan (18, 19), a new opportunity is at hand to create
better investigational tools in the form of highly selective com-
pounds for TSPO. Because of the lipophilic nature of many TSPO
ligands, they can integrate into the lipid membranes of cells and
organelles with ease and, we speculate, cause functional responses
(75, 139). We, therefore, anticipate innovative studies into the
biophysical mechanisms by which selective ligands for the PBR/
TSPO may exert either modified or additional actions in the pres-
ence or absence of TSPO, using the unique opportunity to compare
normally functioning cells and organelles from wild-type and
knockout animals. Such studies have the potential to make a
broader contribution to the understanding of drug activity, where
ligand–membrane interactions may explain functional effects that
receptor–ligand interactions alone cannot.
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SUPPORTING INFORMATION
Additional Supporting Information may be found in the online
version of this article at the publisher’s web-site:
Figure S1. (A) Publication of articles within search terms; refined
by name used for TSPO. Evidence indicates Ro5-4864 has been
replaced by newer ligands targeting TSPO; however, PK11195 is
still widely used as the prototypical TSPO ligand. In spite of the
change in nomenclature, TSPO is still very commonly referred to
in terms of its pharmacological properties (ie, the ability to bind
benzodiazepines in the periphery). (B) Citation of articles within
search terms each year; sorted by name used for TSPO. Articles
using the term “peripheral benzodiazepine,” “PK11195/PK
11195” and “peripheral-type benzodiazepine” receive consider-
ably more citations than articles exclusively using the other search
terms.
Table S1. Clinical trials relating to neuroinflammation using
TSPO ligands (from clinicaltrials.gov).
Table S2. Terms for literature search.
Table S3. TSPO-associated proteins.
Table S4. TSPO ligands.
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